Reading and Resources
Bittner VA, Giugliano RP, Brinton EA, Guyton JR. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. J Clin Lipidol. 2018;12:835-843.
Cuchel M, Bruckert E, Ginsberg H, et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-2157.
Dixon Dl, Pamulapati LG, Bucheit JD, et al. Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2019;21:16.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143.
Hovingh G, Goldberg A, Moriatry P. Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit. J Clin Lipidol. 2017;11:602-616.
National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
Raal F, Rosenson R, Reeskamp L, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-720.
Reeskamp L, Millar J, Wu L, et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL APOB in patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2021;41(5):1753-1759.
Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res. 2021;62:100060.
Tada H, Takamura M, Kawashiri MA. Individualized treatment for patients with familial hypercholesterolemia. J Lipid Atheroscler. 2022;11(1):39-54.
Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: Retrospective cohort study. Lancet. 2022;399(10326):719-728.
Varghese MJ. Familial hypercholesterolemia: A review. Ann Pediatr Cardiol. 2014;7:107-117.
American Heart Association. Familial hypercholesterolemia (FH). Reviewed November 9, 2020. https://www.heart.org/en/health-topics/cholesterol/causes-of-high-cholesterol/familial-hypercholesterolemia-fh
Centers for Disease Control and Prevention (CDC). Cholesterol patient education handouts. Reviewed September 27, 2021. www.cdc.gov/cholesterol/materials_for_patients.htm
Centers for Disease Control and Prevention (CDC). Familial hypercholesterolemia. Reviewed February 10, 2022. https://www.cdc.gov/genomics/disease/fh/FH.htm
Centers for Disease Control and Prevention (CDC). Getting your cholesterol checked. Reviewed September 8, 2020. www.cdc.gov/cholesterol/cholesterol_screening.htm
Ose L. National Lipid Association (NLA). Familial Hypercholesterolemia. An educational booklet for patients with familial hypercholesterolemia. http://nlaresourcecenter.lipidjournal.com/Content/PDFs/FA-Patient-Book-English.pdf
NIH. US National Library of Medicine. ClinicalTrials.gov. www.clinicaltrials.gov